McMichael A, et al. - In 2 phase III, multicenter, randomized, double-blind, placebo- and active comparator-controlled studies (AMAGINE-2/-3), researchers estimated the effectiveness, safety, and health-related quality of life correlated with brodalumab in subjects with the skin of color. They noted similar skin clearance response rates across racial and ethnic subgroups at week 12 and week 52 among subjects who received brodalumab 210 mg Q2W. They also reported higher rates of 75%, 90%, and 100% improvement in Psoriasis Area and Severity Index (PASI) from baseline [as was Static Physician’s Global Assessment (sPGA) score ≤ 1] among subjects who received brodalumab 210 mg Q2W vs subjects who received ustekinumab across all racial and ethnic subgroups. Similar rates of treatment-emergent adverse events (TEAEs) and ≥ 5-point improvement in Dermatology Life Quality Index (DLQI) score across racial and ethnic subgroups were also recorded.